Risedronate-induced Hepatitis.
Phillips
Michael B
MB
D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008107:Liver Diseases / Q000503:physiopathology; D008111:Liver Function Tests; D008134:Long-Term Care; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000188:drug therapy; D000068296:Risedronic Acid; D018570:Risk Assessment; D012720:Severity of Illness Index; D000637:Transaminases / Q000097:blood*
D050071:Bone Density Conservation Agents; D000637:Transaminases; D000068296:Risedronic Acid; D012968:Etidronic Acid